Literature DB >> 19291775

The missense mutation G12D in connexin30.3 can cause both erythrokeratodermia variabilis of Mendes da Costa and progressive symmetric erythrokeratodermia of Gottron.

M A M van Steensel1, A P Oranje, J G van der Schroeff, A Wagner, M van Geel.   

Abstract

Progressive symmetric erythrokeratoderma of Gottron (PSEK) is commonly distinguished from erythrokeratodermia variabilis Mendes da Costa (EKV). However, conclusive proof that the disorders are identical is still lacking. We performed mutation analysis and microsatellite haplotyping in two independently referred patients with PSEK and three patients from a previously published family with EKV. All patients had the same mutation in the GJB4 gene causing the amino acid substitution p.Gly12Asp (G12D). Haplotype analysis showed that all five patients had the same allelic haplotype over 2 Mb covering the disease locus. Apparently, the same GJB4 mutation may cause either an EKV or a PSEK phenotype. A single ancestral founder might have introduced EKV in the Netherlands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291775     DOI: 10.1002/ajmg.a.32744

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  13 in total

1.  Identification of a CDH12 potential candidate genetic variant for an autosomal dominant form of transgrediens and progrediens palmoplantar keratoderma in a Tunisian family.

Authors:  Cherine Charfeddine; Hamza Dallali; Ghaith Abdessalem; Kais Ghedira; Yosr Hamdi; Sahar Elouej; Zied Landoulsi; Valérie Delague; Arnaud Lagarde; Nicolas Levy; Aziz El-Amraoui; Mohamed Samir Boubaker; Sonia Abdelhak; Mourad Mokni
Journal:  J Hum Genet       Date:  2020-01-07       Impact factor: 3.172

Review 2.  Connexin channels in congenital skin disorders.

Authors:  Evelyn Lilly; Caterina Sellitto; Leonard M Milstone; Thomas W White
Journal:  Semin Cell Dev Biol       Date:  2016-01-13       Impact factor: 7.727

3.  Progressive symmetric erythrokeratoderma with unusual associations.

Authors:  Ram Chander; Masarat Jabeen; Meenu Barara; Dinesh Kataria
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

Review 4.  [Skin biopsy of inflammatory skin diseases in childhood-when is it reasonable?]

Authors:  A Böer-Auer; R Fölster-Holst
Journal:  Hautarzt       Date:  2018-07       Impact factor: 0.751

Review 5.  Ichthyoses-A Clinical and Pathological Spectrum from Heterogeneous Cornification Disorders to Inflammation.

Authors:  Dieter Metze; Heiko Traupe; Kira Süßmuth
Journal:  Dermatopathology (Basel)       Date:  2021-05-07

6.  GJB2 Gene Mutations in Syndromic Skin Diseases with Sensorineural Hearing Loss.

Authors:  Sandra Iossa; Elio Marciano; Annamaria Franzé
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

7.  Dominant De Novo Mutations in GJA1 Cause Erythrokeratodermia Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia.

Authors:  Lynn M Boyden; Brittany G Craiglow; Jing Zhou; Ronghua Hu; Erin C Loring; Kimberly D Morel; Christine T Lauren; Richard P Lifton; Kaya Bilguvar; Amy S Paller; Keith A Choate
Journal:  J Invest Dermatol       Date:  2014-11-14       Impact factor: 8.551

8.  Progressive symmetric erythrokeratodermia with delayed intellectual milestones and convulsions.

Authors:  Shyam B Verma; Uwe Wollina
Journal:  Indian Dermatol Online J       Date:  2012-01

9.  Progressive Symmetric Erythrokeratoderma Having Overlapping Features With Erythrokeratoderma Variabilis and Lesional Hypertrichosis: Is Nomenclature "Erythrokeratoderma Variabilis Progressiva" More Appropriate?

Authors:  Vikram K Mahajan; Gayatri Khatri; Pushpinder S Chauhan; Karaninder S Mehta; Rashmi Raina; Mrinal Gupta
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

10.  Late Onset Progressive Symmetric Erythrokeratoderma with Pseudo Ainhum.

Authors:  Gowrappala Shanmukhappa Asha; Dammaningala Venkataramaiah Lakshmi; Kanathur Shilpa; Gorur Kallappa Divya
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.